Phase 10

Savers Value Village, Inc. Reports First Quarter Financial Results and Acquisition of Thrift Store Chain with Seven Locations in Georgia

Retrieved on: 
목요일, 5월 9, 2024
Retail, Home Goods, Discount, Variety, Fashion, Internet, University, CFO, Treasury, Phase 10, Depreciation, Nordstrom, Conference, Webcast, Business, Tax, SVV, Pressure, Acquisition, Interim, Accounting, Economics, GAAP

Savers Value Village, Inc. (NYSE: SVV), (the “Company”) today announced financial results for the thirteen weeks ended March 30, 2024 (the “first quarter”).

Key Points: 
  • Savers Value Village, Inc. (NYSE: SVV), (the “Company”) today announced financial results for the thirteen weeks ended March 30, 2024 (the “first quarter”).
  • Highlights for the First Quarter, Compared to the thirteen weeks ended April 1, 2023
    Net sales increased 2.5% to $354.2 million.
  • Acquisition of Thrift Store Chain with Seven Locations in Atlanta, GA
    On May 6, 2024, the Company acquired 2 Peaches Group, LLC (“2 Peaches”), a thrift store chain with seven locations in the Atlanta, Georgia metropolitan area.
  • A conference call to discuss the first quarter financial results is scheduled for today, May 9, 2024, at 4:30 p.m.

Acacia Research Reports First Quarter 2024 Financial Results

Retrieved on: 
목요일, 5월 9, 2024
Professional Services, Business, Finance, Sale, Investment, Phase 10, Intellectual property, Printronix, Veritone, Webcast, Book value, Exercise, Acquisition, AIP, GAAP, Cryptocurrency

First Quarter 2024 Financial Summary:

Key Points: 
  • First Quarter 2024 Financial Summary:
    Total revenues were $24.3 million, compared to $14.8 million in the same quarter last year.
  • The Intellectual Property business generated $13.6 million in licensing and other revenue during the quarter, compared to $4.2 million in the same quarter last year.
  • Printronix generated $8.8 million in revenue during the quarter, compared to $10.6 million in the same quarter last year.
  • Acacia owns 64% of MalinJ1, which results in a 26% indirect ownership stake in Viamet Pharmaceuticals, Inc. for Acacia.

ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
목요일, 5월 9, 2024
Mortality, EP, KPI, FTE, Vaccine-naive, Risk, PIN, Phase 10, FY, ADMA, Immunotherapy, Conference, Plasma, Vaccine, Total revenue, Growth, Patent, Patient, Marketing, Death, Interim, Adjustment, GAAP, Overalls, Community-acquired pneumonia, Pet industry

ET

Key Points: 
  • ET
    RAMSEY, N.J. and BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its first quarter 2024 financial results and provided a business update.
  • “ADMA’s commercial success continues to unfold, and during the first quarter of 2024, we surpassed our financial expectations and delivered compounding earnings growth.
  • First Quarter 2024 Financial Results:
    Total revenues were $81.9 million for the quarter ended March 31, 2024, as compared to $56.9 million for the quarter ended March 31, 2023, an increase of $25.0 million, or approximately 44%.
  • As a result, ADMA achieved a corporate gross margin of 48% in the first quarter of 2024 as compared to 29% in the first quarter of 2023.

RAPT Therapeutics Reports First Quarter 2024 Financial Results

Retrieved on: 
목요일, 5월 9, 2024
FDA, Phase 10, Research, Consultant, Patient, Liver failure, Inflammation, Clinical trial, Atopic dermatitis, Therapy, Asthma, SAN, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 2024.
  • Concurrently, we are continuing our investigation and analysis of the serious adverse event that triggered the clinical hold.”
    Financial Results for the First Quarter March 31, 2024
    First Quarter Ended March 31, 2024
    Net loss for the first quarter of 2024 was $30.5 million, compared to $29.3 million for the first quarter of 2023.
  • Research and development expenses for the first quarter of 2024 were $24.8 million, compared to $25.6 million for the same period in 2023.
  • General and administrative expenses for the first quarter of 2024 were $7.7 million, compared to $6.0 million for the same period in 2023.

Portman Ridge Finance Corporation Announces First Quarter 2024 Financial Results

Retrieved on: 
수요일, 5월 8, 2024
CLO, Total, Investment, Par, Phase 10, NAV, NII, GAAP

NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Portman Ridge Finance Corporation (Nasdaq: PTMN) (the “Company” or “Portman Ridge”) announced today its financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Continued Share Repurchase Program: Total of 51,015 Shares for an Aggregate Cost of Approximately $1.0 Million Repurchased During the First Quarter; Accretive to NAV by $0.02 Per Share
    NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Portman Ridge Finance Corporation (Nasdaq: PTMN) (the “Company” or “Portman Ridge”) announced today its financial results for the first quarter ended March 31, 2024.
  • Net investment income ("NII") for the first quarter of 2024 was $6.2 million ($0.67 per share) as compared to $11.2 million ($1.18 per share) in the fourth quarter of 2023.
  • Declared stockholder distribution of $0.69 per share for the second quarter of 2024, payable on May 31, 2024, to stockholders of record at the close of business on May 21, 2024.
  • Ted Goldthorpe, Chief Executive Officer of Portman Ridge, stated, “Following the strong earnings we saw in 2023, Portman Ridge is off to a solid start in 2024, ending the first quarter with net deployment and a robust pipeline.

Backblaze Announces First Quarter 2024 Financial Results

Retrieved on: 
수요일, 5월 8, 2024
Cloud, Education, Motion, Investment, ARR, Film, Cloud storage, State, Phase 10, Yoy, Carahsoft, Webcast, National Association, Local government, TPN, SLED, NRR, SAN

SAN MATEO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Backblaze, Inc. (Nasdaq: BLZE), a leading specialized storage cloud platform, today announced results for its first quarter ended March 31, 2024.

Key Points: 
  • SAN MATEO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Backblaze, Inc. (Nasdaq: BLZE), a leading specialized storage cloud platform, today announced results for its first quarter ended March 31, 2024.
  • “We had a record start to 2024, with dramatically improved financial metrics year over year including Q1 revenue growth of 28% compared to 20%, and adjusted EBITDA margin of 6% versus -12%,” said Gleb Budman, CEO of Backblaze.
  • First Quarter 2024 Operational Highlights:
    Annual recurring revenue (ARR) was $122.1 million, an increase of 27% YoY.
  • Based on information available as of the date of this press release,
    For the second quarter of 2024 we expect:
    For full-year 2024 we expect:
    Today we announced that our Chief Financial Officer, Frank Patchel, plans to retire later this year.

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
수요일, 5월 8, 2024
Vaccination, Public, Advisory Committee, Net, Ageing, Tolerability, Investment, PCV15, PCV, Safety, Phase 10, Infant, Infection, Trial of the century, Conference, Growth, Administration, Lonza, Immunization, Exercise, Research and development, Bank, ACIP, Stage 2, Initiate, PCV20, G&A, SAN, End, Genetically modified bacteria, IPD, Vaccine

SAN CARLOS, Calif., May 08, 2024 (GLOBE NEWSWIRE) --  Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • “We also continue to progress our early-stage pipeline led by VAX-A1, a vaccine candidate designed to prevent Group A Strep infections.
  • The aggregate gross proceeds to Vaxcyte from this offering were $862.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.
  • The March 31, 2024 amount includes the $816.5 million in net proceeds from the follow-on offering completed in February 2024.
  • As of March 31, 2024, Vaxcyte had incurred $101.8 million in total capital and facility buildout expenditures that were reflected on the Company’s balance sheet as of that date.

SBM Offshore First Quarter 2024 Trading Update

Retrieved on: 
수요일, 5월 8, 2024
Prosperity, CFO, Technip Energies, Lease, Memorandum of understanding, SBM, FPSO, Phase 10, SBM Offshore, Engineering, MPF, FEED, Operate, Share repurchase, Recycling, First, Interest, Q&A

EkWiL – SBM Offshore and Technip Energies have announced the signing of a MoU for the creation of a joint venture entity, EkWiL.

Key Points: 
  • EkWiL – SBM Offshore and Technip Energies have announced the signing of a MoU for the creation of a joint venture entity, EkWiL.
  • The dividend payment is scheduled for May 10, 2024 to all shareholders of record as at April 17, 2024.
  • SBM Offshore has scheduled a conference call, which will be followed by a Q&A session, to discuss the First Quarter 2024 Trading Update.
  • SBM Offshore designs, builds, installs and operates offshore floating facilities for the offshore energy industry.

Portillo’s Inc. Announces First Quarter 2024 Financial Results

Retrieved on: 
화요일, 5월 7, 2024
L.L.C, Total, Salad, Sustainable Forestry Initiative, Phase 10, Restaurant, Greek salad, Income tax, Food, Marketing, Adjustment, Advertising, Running, GAAP, Food delivery

*For the quarter ended March 31, 2024, same-restaurant sales compares the 13 weeks from January 1, 2024 through March 31, 2024 to the 13 weeks from January 2, 2023 through April 2, 2023.

Key Points: 
  • *For the quarter ended March 31, 2024, same-restaurant sales compares the 13 weeks from January 1, 2024 through March 31, 2024 to the 13 weeks from January 2, 2023 through April 2, 2023.
  • Same-restaurant sales declined 1.2% during the quarter ended March 31, 2024, compared to 9.1% same-restaurant sales growth during the same quarter in 2023.
  • The twelve restaurants opened in 2023 and one restaurant opened during the quarter ended March 31, 2024 positively impacted revenues by approximately $14.4 million in the quarter ended March 31, 2024.
  • In the quarter ended March 31, 2024, commodity inflation was 4.8%, compared to 8.9% for the quarter ended March 26, 2023.

RioCan Reports First Quarter Results - Strong Leasing Results Driven by Accelerated Demand for High-Quality RioCan Space

Retrieved on: 
화요일, 5월 7, 2024
Commercial Building & Real Estate, Construction & Property, REIT, Phase 10, NLA, The, Trust, Acquisition, Security (finance)

During the First Quarter, $62.9 million or 54,000 square feet of properties under development were transferred to income producing properties.

Key Points: 
  • During the First Quarter, $62.9 million or 54,000 square feet of properties under development were transferred to income producing properties.
  • The retail component is 94% leased, with more than half of the space open and operating.
  • As market conditions permit, RioCan provides mezzanine financing, earning interest income at attractive rates relative to its cost of capital.
  • During Q1 2024, RioCan issued $68.0 million of new loans and $30.6 million of existing loans were repaid.